Tigecycline Usage In Cancer Patients With Refractory Pneumonia: A Report On 38 Cases In A Single Institution

Roy F Chemaly, MD, MPH, Ray Hachem, MD, Santosh Hanmod, MD, Javier Adachi, MD, Holly Hogan, PharmD,Victor Mulanovich, MD, Dimitrios P Kontoyiannis, MD, Amar Safdar, MD, Issam I Raad, MD, Kenneth V.I. , Rolston, MD

Author address: 

Department of Infectious Diseases, Infection Control and Employee Health, University of Texas, MD Anderson Cancer Center, Houston, TX

Abstract: 

Background: Tigecycline (TG), first in a new class of Glycylclines, is a novel agent approved for treatment of complicated soft tissue and intraabdominal infections in adults. Clinical data on the safety and efficacy of TG in cancer pts with pneumonia is lacking. Methods: We reviewed records of cancer pts with pneumonia treated with TG for >72 h between Sept’05 and Sept’06. Data collection included demographics, cancer type, indication for TG, side effects and outcome. Results: Thirty-eight pts with pneumonia were identified, 4 (10%) of them had ventilatorassociated pneumonia. Median age was 56 years (23-79 y). Most pts (28, 74%) had hematologic malignancies, including 14 allogeneic HSCT pts; 13 pts (34%) were neutropenic (ANC72 h between Sept’05 and Sept’06. "¢ Data collection included demographics, cancer type, indication for TG, side effects and outcome. Table: 1 Patient characteristics and risk factors for infection Table: 2 Information about Tigecycline use Results 56256;56451; Thirty-eight pts with refractory pneumonia were identified including 25 males and 13 females. 56256;56451; Most of the patients [28(74%)] had hematological malignancies. Clinical Improvement: 24 (63%) 56256;56451; 12 (50%) patients were in ICU at the time of initiation of TG 56256;56451; 10 (42%) patients were on ventilator support and successfully weaned to spontaneous ventilation. 56256;56451; 3(13%) patients had ventilator associated pneumonia 56256;56451; 8 (33%) patients had neutropenia (ANC
2007

abstract No: 

P729

Full conference title: 

17th European Congress of Clinical Microbiology and Infectious Diseases and 25th International Congress of Chemotherapy
    • ECCMID 17th (2007)